Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesSafety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
Biologics: targets & therapy, 01/08/09
Fervenza FC et al. - Kidney involvement with progressive loss of kidney function (Fabry nephropathy) is an important complication of Fabry disease, an X-linked lysosomal storage disorder arising from deficiency of ?-galactosidase activity. Clinical trials have shown that enzyme replacement therapy (ERT) with recombinant human ?-galactosidase clears globotriaosylceramide from kidney cells, and can stabilize kidney function in patients with mild to moderate Fabry nephropathy.
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment with Olanzapine is Associated with Modulation of the Default Mode Network in Patients with Schizophrenia
Neuropsychopharmacology, 12/15/09
An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas
Journal of Pharmacy and Pharmacology, 12/15/09
Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up
Acta Neurologica Scandinavica, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor